DrugInfoSys

Repaglinide

Drug #994

Repaglinide is oral hypoglycemic agent. The onset of action is rapid but the duration of action is short. Repaglinide is used in the treatment of non-insulin dependent diabetes. It may also reduce the long term cardiovascular, cerebrovascular and renal effects of diabetes.

← Previous drugNext drug →

Primary Characteristics

It belongs to Piperidinobenzyl.

It belongs to Insulin agonist pharmacological group on the basis of mechanism of action and also classified in Antidiabetic Agent pharmacological group.

Molecular Weight: 452.6 · Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Repaglinide.

Molecular structure of Repaglinide

Pharmacokinetics

Absorption: Repaglinide has an oral bioavailability is 56% (±7%).

Distribution: Repaglinide has a volume of distribution is 0.52(0.35-0.69)l/kg. plasma protein binding is > 98 %.

Elimination: plasma half-life is 0.8(0.6-1)hr, renal excretion is 1.45(0.3-2.6)%.

Advertisement

Indications

Repaglinide is primarily indicated in conditions like NIDDM, Type II diabetes mellitus.

Contraindications

Repaglinide is contraindicated in conditions like Coma, Diabetic ketoacidosis.

Dosage

Repaglinide's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
1.25 mg1.25 mgEvery 8hPOMaximum dose: 4 mg.
Paediatric Dosage (20kg)
0 – 0——Not recommended in this age group
Neonatal Dosage (3kg)
0 – 0——Not recommended in this age group

Drug Interactions

15 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Repaglinide are Nausea, Sweating , Seizures, Convulsions , Coma, Cerebral damage.

Repaglinide is known to cause more or less tolerable side effects which are usually transient. These include Allergy , Anaphylactoid reactions, Bronchitis , Chest pain, Constipation , Diarrhea, Headache, Hypoglycemia, Nausea and vomiting, Sinusitis , Thrombocytopenia.

Warnings / Precautions

Use with caution in patients with hepatic impairment. All oral hypoglycemic agents are capable of producing hypoglycemia. Proper patient selection, dosage and the instruction to the patients are important to avoid hypoglycemic episodes. It may be necessary to discontinue repaglinide and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery). At higher dosages sulfonylurea may block the ATP-sensitive potassium channel, which may correspond to an increase risk of cardiovascular events. Avoid the use of sulfonylurea at higher dosages (repaglinide daily doses >1.5 mg).

Interference in Pathology

Repaglinide may interfere in the diagnosis of Abnormal LFTs .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs
0.5 mg1 mg2 mg

Storage Conditions

Repaglinide should be stored .

Drug Classification

  1. 1.18.7.2 — Oral hypoglycemics

Manufacturers

Manufacturers of Repaglinide in Pakistan:

CirinGetzLexiconMassNovinsNovoRaazeeScotmannWilshire